Cincinatti, OH—While previous studies suggested adverse events in women aged 60 to 90 years treated with a monclonal antibody for osteoporosis, new research offers encouraging news: those problems didn’t increase after another 3 years of treatment with denosumab. Furthermore, according to the study in the Journal of Bone and Mineral Research, no increase in adverse effects was identified in women who switched from 3 years of placebo to 3 years of denosumab therapy versus those treated for the initial 3 years. Mercy Health–led researchers also questioned whether the adverse events—including back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis, which are listed as potential denosumab side effects—were necessarily related to participation the clinical trial. Overall, study authors said the drug had an “excellent safety and tolerability profile.”

« Click here to return to The MTM Review.